Assessment of Inactivation Procedures for SARS-CoV-2
Open Access
- 28 May 2020
- preprint content
- Published by Cold Spring Harbor Laboratory
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19), presents a challenge to laboratorians and healthcare workers around the world. Handling of biological samples from individuals infected with the SARS-CoV-2 virus requires strict biosafety and biosecurity measures. Within the laboratory, non-propagative work with samples containing the virus requires, at minimum, Biosafety Level-2 (BSL-2) techniques and facilities. Therefore, handling of SARS-CoV-2 samples remains a major concern in areas and conditions where biosafety and biosecurity for specimen handling is difficult to maintain, such as in rural laboratories or austere field testing sites. Inactivation through physical or chemical means can reduce the risk of handling live virus and increase testing ability worldwide. Herein we assess several chemical and physical inactivation techniques employed against SARS-CoV-2 isolates from Cambodian COVID-19 patients. This data demonstrates that all chemical (AVL, inactivating sample buffer and formaldehyde) and heat treatment (56°C and 98°C) methods tested completely inactivated viral loads of up to 5 log10.Keywords
This publication has 20 references indexed in Scilit:
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- Evaluation of heating and chemical protocols for inactivating SARS-CoV-2Published by Cold Spring Harbor Laboratory ,2020
- Validation of a Lysis Buffer Containing 4 M Guanidinium Thiocyanate (GITC)/ Triton X-100 for Extraction of SARS-CoV-2 RNA for COVID-19 Testing: Comparison of Formulated Lysis Buffers Containing 4 to 6 M GITC, Roche External Lysis Buffer and Qiagen RTL Lysis BufferPublished by Cold Spring Harbor Laboratory ,2020
- Unreliable Inactivation of Viruses by Commonly Used Lysis BuffersApplied Biosafety, 2017
- Determination of 50% endpoint titer using a simple formulaWorld Journal of Virology, 2016
- Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample TypeJournal of Clinical Microbiology, 2015
- Emerging Infectious Diseases and Public Health Policy: Insights from Cambodia, Hong Kong and IndonesiaTransboundary and Emerging Diseases, 2013
- Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoVJournal of Virological Methods, 2004
- Virus inactivation by nucleic acid extraction reagentsJournal of Virological Methods, 2004
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986